We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
Read MoreHide Full Article
Charles River Laboratories (CRL - Free Report) recently announced a partnership with Korean biotechnology company Curigin for adenoviral vector production. Per the collaboration, Curigin, which develops oncolytic ribonucleic acid interference (RNAi) gene therapies, will leverage Charles River's expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials.
However, the financial terms of the deal were not disclosed.
A Few Words on the Deal
Curigin’s anticancer gene therapy products utilize genetically engineered viruses and advanced RNAi technology to quickly and accurately block key disease-specific genetic signal pathways. This process effectively switches off genes responsible for tumor growth. These gene therapies can be offered to patients who have not been treated with conventional cancer drugs.
Curigin’s lead candidate is CA102, a genetically engineered adenovirus for bladder cancer. Curigin currently expects to submit an Investigational New Drug application for CA102 to the FDA within this year.
Meanwhile, CRL has standardized protocols for cell culture, transfection, and downstream purification, as well as a validated platform process with a proven track record. According to the company, these high-yield, optimized methods increase the speed of clinical manufacturing by reducing process development time and costs while ensuring the highest quality production.
Image Source: Zacks Investment Research
In this regard, Charles River noted that bladder cancer is recognized as the 10th most common type of cancer globally (according to the World Cancer Research Fund).
Industry Prospects
Per a Research report, the global plasmic DNA manufacturing market size was valued at $1.29 billion in 2022 and is expected to witness a compound annual growth rate of 17.63% by 2030.
The increasing awareness about cell and gene therapy boosts the industry’s growth. This is mainly due to a rise in cell and gene therapy products, which are used for the treatment of various diseases globally, and the availability of approved gene therapy products.
Recent Other Alliances
Earlier this month, Charles River formed a plasmid DNA manufacturing collaboration with INADcure Foundation. INADcure is a non-profit organization to support the development of treatments for Infantile Neuroaxonal and other forms of PLA2G6-related neurodegeneration. This partnership will leverage Charles River’s CDMO expertise in high-quality plasmid DNA production to manufacture its leading candidate for Phase I/II clinical trials.
In May 2023, Charles River together with Wheeler Bio, a CDMO, announced an agreement to implement RightSource at Wheeler Bio’s current good manufacturing practice biologics manufacturing facility in Oklahoma City, OK.
Price Performance
In the past year, shares of the company have declined 2.5% compared with the industry’s fall of 16.3%.
Penumbra’s stock has risen 175.8% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and at $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have improved 34.2% in the past year against the industry’s 22.7% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS have increased from $3.29 to $3.55 for 2023 in the past 30 days. Shares of the company have increased 40.5% in the past year against the industry’s 22.7% decline.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
Charles River Laboratories (CRL - Free Report) recently announced a partnership with Korean biotechnology company Curigin for adenoviral vector production. Per the collaboration, Curigin, which develops oncolytic ribonucleic acid interference (RNAi) gene therapies, will leverage Charles River's expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials.
However, the financial terms of the deal were not disclosed.
A Few Words on the Deal
Curigin’s anticancer gene therapy products utilize genetically engineered viruses and advanced RNAi technology to quickly and accurately block key disease-specific genetic signal pathways. This process effectively switches off genes responsible for tumor growth. These gene therapies can be offered to patients who have not been treated with conventional cancer drugs.
Curigin’s lead candidate is CA102, a genetically engineered adenovirus for bladder cancer. Curigin currently expects to submit an Investigational New Drug application for CA102 to the FDA within this year.
Meanwhile, CRL has standardized protocols for cell culture, transfection, and downstream purification, as well as a validated platform process with a proven track record. According to the company, these high-yield, optimized methods increase the speed of clinical manufacturing by reducing process development time and costs while ensuring the highest quality production.
Image Source: Zacks Investment Research
In this regard, Charles River noted that bladder cancer is recognized as the 10th most common type of cancer globally (according to the World Cancer Research Fund).
Industry Prospects
Per a Research report, the global plasmic DNA manufacturing market size was valued at $1.29 billion in 2022 and is expected to witness a compound annual growth rate of 17.63% by 2030.
The increasing awareness about cell and gene therapy boosts the industry’s growth. This is mainly due to a rise in cell and gene therapy products, which are used for the treatment of various diseases globally, and the availability of approved gene therapy products.
Recent Other Alliances
Earlier this month, Charles River formed a plasmid DNA manufacturing collaboration with INADcure Foundation. INADcure is a non-profit organization to support the development of treatments for Infantile Neuroaxonal and other forms of PLA2G6-related neurodegeneration. This partnership will leverage Charles River’s CDMO expertise in high-quality plasmid DNA production to manufacture its leading candidate for Phase I/II clinical trials.
In May 2023, Charles River together with Wheeler Bio, a CDMO, announced an agreement to implement RightSource at Wheeler Bio’s current good manufacturing practice biologics manufacturing facility in Oklahoma City, OK.
Price Performance
In the past year, shares of the company have declined 2.5% compared with the industry’s fall of 16.3%.
Zacks Rank and Key Picks
Charles River carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus (LNTH - Free Report) and Haemonetics (HAE - Free Report) . While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Haemonetics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has risen 175.8% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and at $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have improved 34.2% in the past year against the industry’s 22.7% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS have increased from $3.29 to $3.55 for 2023 in the past 30 days. Shares of the company have increased 40.5% in the past year against the industry’s 22.7% decline.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.24%.